Stay Updated

L-Carnitine

Also known as: Levocarnitine, L-carnitine, Carnitine, L-β-hydroxy-γ-N-trimethylaminobutyric acid

3 notable studies · 4 references

View Supplier Listings Take This L-Carnitine Study With You

TLDR

L-Carnitine is an endogenous non-peptide molecule essential for transporting long-chain fatty acids into mitochondria for β-oxidation and is an established treatment for true carnitine deficiency, while supplementation in broader populations may produce modest improvements in weight and some metabolic measures but does not support the simplistic claim that adding more carnitine automatically causes substantial fat burning or energy enhancement.

Research Supports

  • Established treatment for genetic primary carnitine deficiency
  • Studied for modest effects on body weight and body composition
  • Investigated for cardiometabolic effects in type 2 diabetes and impaired glucose tolerance
  • Studied in hemodialysis patients with documented carnitine deficiency and cardiac dysfunction
  • Examined in cardiovascular outcomes after acute myocardial infarction

Observations Reported in Research

  • 37-RCT meta-analysis (2020, n=2,292): ~1.21 kg greater weight loss and ~2.08 kg fat-mass reduction on average
  • Hemodialysis RCT (2016): ejection fraction rose ~5.4 percentage points vs. no change in controls over 12 months
  • Mirrafiei et al., 2024 (21 trials, n=2,041, type 2 diabetes): small reductions in BMI, HbA1c, and LDL per 1 g/day
  • 2013 meta-analysis (13 trials, n=3,629, post-MI): reduced mortality, arrhythmias, and angina, but not reinfarction
  • Waist circumference and body-fat percentage were not significantly changed in the weight-loss meta-analysis

These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.

At a Glance

Classification: Endogenous quaternary ammonium compound; mitochondrial fatty-acid transport cofactor; conditionally essential nutrient

First important distinction: L-Carnitine is not a peptide. It is a small endogenous molecule essential to the transport of long-chain fatty acids into mitochondria, where they can undergo β-oxidation. The carnitine shuttle includes: CPT1 → CACT → CPT2. Without adequate carnitine transport, long-chain fatty-acid oxidation can become severely impaired. Genetic primary carnitine deficiency can cause hypoketotic hypoglycemia, liver dysfunction, skeletal/cardiac myopathy and potentially dangerous arrhythmias. So the biological claim: Carnitine is necessary for long-chain fat oxidation is rock solid. But the popular conclusion: Therefore extra L-carnitine makes healthy people burn lots more body fat doesn't follow automatically. Interestingly, supplementation trials do show a small average weight-loss effect—just nowhere near what “fat-burning” marketing might imply. A 37-RCT meta-analysis found an average difference of about 1.2 kg.

What Is L-Carnitine?

Humans obtain carnitine through both: • Endogenous synthesis • Diet, especially animal-derived foods. Its best-established role is moving long-chain fatty-acid groups through the otherwise impermeable inner mitochondrial membrane. The simplified pathway: Long-chain fatty acid ↓ fatty acyl-CoA ↓ CPT1 + carnitine ↓ acylcarnitine ↓ CACT transports it into mitochondrial matrix ↓ CPT2 ↓ fatty acyl-CoA regenerated ↓ β-oxidation ↓ energy production. Carnitine also helps manage mitochondrial acyl-group balance through formation/export of acylcarnitines.

What Are Researchers Studying?

Primary carnitine deficiency

This is one of L-carnitine's clearest therapeutic contexts. Mutations affecting the high-affinity OCTN2/SLC22A5 carnitine transporter can cause profound cellular carnitine deficiency and excessive urinary loss. Clinical consequences can include: • Hypoketotic hypoglycemia • Hepatic dysfunction • Skeletal myopathy • Cardiomyopathy • Arrhythmia. The condition responds to pharmacological L-carnitine replacement. This is replacement of a physiologically deficient molecule, not generic metabolic enhancement.

Mitochondrial fatty-acid oxidation

This is foundational carnitine biology. Long-chain fatty acids require the carnitine shuttle to enter the mitochondrial matrix for β-oxidation. But there's a major logic trap: Carnitine is required for fat oxidation doesn't mean: carnitine availability is the rate-limiting factor for fat loss in every healthy person. If tissue carnitine is already adequate, adding more does not necessarily produce proportionally greater fatty-acid oxidation.

Weight loss

Here the answer is more interesting than either the supplement hype or a blanket dismissal. A meta-analysis of 37 randomized trials involving 2,292 participants found L-carnitine supplementation was associated with: • −1.21 kg body weight • −0.24 kg/m² BMI • −2.08 kg fat mass on average. However, waist circumference and body-fat percentage weren't significantly changed, and when analysis was restricted to higher-quality trials, only the body-weight effect remained clearly supported. A 2025 umbrella meta-analysis similarly found statistically significant but relatively modest reductions in weight, BMI and waist circumference across existing meta-analyses. So Aminodex should say: L-carnitine may produce modest average weight reduction in some populations. Not: L-carnitine is a powerful fat burner.

Type 2 diabetes and metabolic health

A 2024 meta-analysis of 21 randomized trials involving 2,041 people with type 2 diabetes found small improvements in several cardiometabolic measures. For each 1 g/day increment analyzed, reported effects included approximately: • BMI −0.37 kg/m² • HbA1c −0.16 percentage points • LDL cholesterol −0.11 mmol/L. The evidence certainty varied substantially by outcome. Another 21-trial analysis involving 2,900 participants with impaired glucose tolerance or diabetes reported improvements across several lipid, glucose and inflammatory markers. These are potentially meaningful research signals—but still generally modest adjunctive effects, not evidence that L-carnitine substitutes for established diabetes therapies.

Hemodialysis-associated carnitine deficiency

Carnitine abnormalities can occur in patients receiving long-term hemodialysis. In a randomized study of hemodialysis patients with documented carnitine deficiency and left-ventricular hypertrophy, oral levocarnitine was associated with improved ejection fraction over 12 months compared with control. Again, the context matters enormously: deficient hemodialysis population ≠ healthy person seeking more energy.

Cardiovascular disease

Carnitine has a substantial cardiovascular research literature. A 2013 meta-analysis of 13 controlled trials involving 3,629 patients after acute myocardial infarction reported reductions in mortality, ventricular arrhythmias and angina, although not reinfarction or heart failure. Those findings are interesting, but much of this literature predates modern post-MI therapy, so its relevance alongside contemporary standard-of-care treatment needs careful interpretation.

Exercise and energy

Carnitine's mitochondrial role makes the marketing connection to “energy” intuitively attractive. But: required for cellular fatty-acid metabolism does not mean: extra carnitine reliably produces more subjective energy or athletic performance in carnitine-replete adults. The research varies by: • Population • Training status • Exposure duration • Carnitine formulation • Outcome. So Aminodex should avoid a generic: “boosts energy” claim.

How Does It Work?

The central mechanism is the carnitine shuttle: Fatty acyl-CoA ↓ CPT1 Transfers the fatty acyl group onto carnitine. ↓ Acylcarnitine ↓ CACT / SLC25A20 Moves acylcarnitine across the inner mitochondrial membrane. ↓ CPT2 Transfers the acyl group back to CoA. ↓ Fatty acyl-CoA ↓ β-oxidation ↓ ATP-generating metabolism. That's much more precise than saying: “L-carnitine burns fat.” It enables mitochondrial transport necessary for long-chain fatty-acid oxidation.

What Does the Research Show?

Human research

VERY HIGH for carnitine physiology and deficiency replacement. HIGH for treatment of primary systemic carnitine deficiency. MODERATE for modest weight/body-composition effects. MODERATE and population-dependent for several metabolic/cardiovascular applications. MIXED for broad performance/energy claims in otherwise healthy people.

Animal research

EXTENSIVE. Carnitine transport, mitochondrial fatty-acid oxidation, genetic deficiencies and metabolic regulation are exceptionally well characterized.

In-vitro research

EXTENSIVE. The carnitine shuttle's enzymes and transporters have been studied at biochemical, cellular, genetic and structural levels.

Notable Studies

Effects of L-Carnitine Supplementation on Weight Loss and Body Composition: A Systematic Review and Meta-Analysis of 37 Randomized Controlled Clinical Trials with Dose-Response Analysis

human

2020

Thirty-seven randomized trials with 2,292 participants were pooled. L-carnitine was associated with approximately 1.21 kg greater weight reduction, with smaller changes in BMI and reported fat mass. Higher-quality trials supported the body-weight effect but not all body-composition endpoints.

Limitations: Considerable variation in populations and interventions; statistically significant average effects were modest; results don't support dramatic “fat-burning” claims.

View publication →

Levocarnitine Improves Cardiac Function in Hemodialysis Patients With Left Ventricular Hypertrophy: A Randomized Controlled Trial

human

2016

Hemodialysis patients with documented carnitine deficiency and left-ventricular hypertrophy were randomized to levocarnitine or control. Among analyzed participants, ejection fraction increased by about 5.4 percentage points in the treatment group and did not meaningfully change in controls.

Limitations: Open-label; substantial attrition from randomized to analyzed population; specialized deficient hemodialysis population limits generalization.

View publication →

The Effects of L-Carnitine Supplementation on Weight Loss, Glycemic Control, and Cardiovascular Risk Factors in Patients With Type 2 Diabetes

human

Mirrafiei A, Jayedi A, Shab-Bidar S · 2024

Twenty-one trials involving 2,041 people with type 2 diabetes were analyzed. Supplementation was associated with small improvements in BMI, HbA1c, LDL cholesterol, triglycerides, total cholesterol and fasting glucose, although certainty and heterogeneity differed by outcome.

Limitations: Significant heterogeneity for several endpoints; changes were generally modest and don't establish L-carnitine as a substitute for established metabolic therapy.

View publication →

What We Still Don't Know

• Which nondeficient populations benefit meaningfully from supplementation • Which formulations are optimal for particular outcomes • How baseline tissue carnitine status modifies response • How much modest weight reduction is clinically meaningful • Whether metabolic improvements persist long term • Which exercise populations reliably benefit • Whether effects seen in deficient/dialysis populations generalize at all to healthy people • How supplementation interacts with the gut microbiome and downstream carnitine metabolites over long periods • Whether older cardiovascular findings translate fully to modern treatment settings.

Related Compounds

Lipo-C

Take the L-Carnitine research with you.

Get the Aminodex L-Carnitine Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.

One-time email. We do not add you to any mailing list.

Sources & References

  1. Longo N, et al. Disorders of carnitine transport and the carnitine cycle.
  2. Carnitine transport and fatty acid oxidation.
  3. Asadi M, et al. Effects of L-carnitine supplementation on weight loss and body composition: systematic review and meta-analysis of 37 randomized controlled clinical trials.
  4. Mirrafiei A, Jayedi A, Shab-Bidar S. Effects of L-carnitine supplementation on weight loss, glycemic control, and cardiovascular risk factors in patients with type 2 diabetes.

Supplier Listings

A directory of relevant research suppliers for this compound is not yet available.